Auditing protein therapeutics management by professional APCs: toward prevention of immune responses against therapeutic proteins.
Alloimmunization is a crippling concern in the management of patients undergoing administration of protein therapeutics as evidenced in replacement therapy and other treatment procedures. Several issues in the genesis and modulation of such deleterious immune responses have been studied. While authors have focused on the downstream events of the specific immune response and suggested modification of protein therapeutics to eliminate epitopes that interact with B cell receptors, T cell receptors, or MHCII molecules, the mechanisms underlying Ag interaction with APCs, a step upstream of immune effectors, have been grossly neglected. We wish to emphasize that the recent knowledge in understanding the capacities of an APC to handle an Ag and the importance of the surrounding microenvironment in this process are crucial for designing novel protein therapeutics with reduced immunogenicity.
Dasgupta
Suryasarathi
S
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie-Paris6, UMR S 872, Paris, F-75006 France. surya.dasgupta@gmail.com
Bayry
Jagadeesh
J
André
Sebastien
S
Dimitrov
Jordan D
JD
Kaveri
Srinivas V
SV
Lacroix-Desmazes
Sebastien
S
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D004705:Endocytosis / Q000276:immunology; D006801:Humans; D007125:Immunogenetics; D007249:Inflammation / Q000276:immunology / Q000378:metabolism; D011506:Proteins / Q000276:immunology*
D011506:Proteins